Clinical Associate Professor Amanda is an experienced dermatologist from Hamilton. She is passionate about dermoscopy, teledermatology and online health education for patients and their doctors, but is happy to talk and write about a wide variety of dermatological topics. 1. Dermatologist, Dept of Dermatology, Waikato DHB;
2. HonoraryAssociate Professor Waikato Clinical School, University of Auckland;
3. Private practice at Tristram Clinic;
4. President and Website Manager New Zealand Dermatological Society Incorporated;
5. Diagnosing consultant for MoleMap NZ
6. Member of National Melanoma Standards Working Group
In 2012, awarded Honorary Membership of American Academy of Dermatology and International Honorary Membership of American Dermatological Association http://dermnetnz.org; http://anzvs.org; http://tristramclinic.co/nz
oakley@wave.co.nz
Phone: 027 271-6985 (urgent calls only)
| Psoriasis: assessment, treatment and monitoring
AbbVie Breakfast Session |
|||
| Saturday, 14 June 2014 | Start 7:00am | Duration: 60mins | Baytrust |
| The dermatology part of this breakfast session will be mainly concerned with chronic plaque psoriasis. A brief review of the most common autoimmune inflammatory skin disorders will include psoriasis, eczema, vitiligo, alopecia areata, lichen sclerosus, morphoea, lichen planus and chronic spontaneous urticaria. Multiple autoimmune diseases can coexist. Chronic plaque psoriasis is strongly associated with autoimmune arthropathy and enthesitis, inflammatory bowel disease and uveitis. To decide whether to refer your patient to a dermatologist, assessment should include the severity and extent of the disease, and its impact on the patient; the Dermatology Life Quality Index is validated and useful. Mild disease can be managed in general practice. Treatment depends on specific clinical features, objective and subjective severity, sites affected, response to previous treatment and chronicity. Treatment escalation in psoriasis involves topical therapies, phototherapy, methotrexate, acitretin, ciclosporin and biologic agents (anti-TNFs, i.e. adalimumab, etanercept and infliximab; and anti IL12/23, i.e. ustekinumab). Specialists and primary care physicians commonly share care, so what to monitor will be covered in some detail. | |||